New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 8, 2014
10:36 EDTIGT, DKS, OREX, FDO, ULTA, COV, DTV, SHPG, ESIOptions with increasing implied volatility
Options with increasing implied volatility: OREX ESI COV DKS SHPG ULTA IGT DTV FDO
News For OREX;ESI;COV;DKS;SHPG;ULTA;IGT;DTV;FDO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
February 23, 2015
07:55 EDTSHPGJefferies says other bidders may emerge for Salix
Jefferies says it could envision other bidders emerging for Salix (SLXP) and points out recent media reports have suggested Shire (SHPG) and Endo (ENDP) have considered making a bid for the company. It lists AstraZeneca (AZN) and Takeda as others who could have possible interest in Salix. The firm believes Valeant (VRX) could afford to pay more for Salix should other bidders emerge.
07:38 EDTDTVComcast, AT&T deals could be delayed by document access case, WSJ says
Subscribe for More Information
05:33 EDTDTVDirecTV downgraded to Hold from Buy at Brean Capital
Subscribe for More Information
February 22, 2015
18:04 EDTSHPGShire completes acquisition of NPS Pharma
Shire (SHPG) announces the successful completion of the tender offer for all of the outstanding shares of NPS Pharmaceuticals (NPSP) and the subsequent acquisition of NPS Pharma.The tender offer expired at 12:00 midnight, New York City time, at the end of Friday, February 20, and was not extended. As of the expiration of the tender offer, a total of approximately 88,869,118 common shares of NPS Pharma had been validly tendered and not withdrawn pursuant to the tender offer, representing approximately 81.7% of the outstanding common shares of NPS Pharma. All shares that were validly tendered and not withdrawn pursuant to the tender offer were accepted for payment. After the acceptance of shares that were validly tendered and not withdrawn pursuant to the tender offer, Shire completed the acquisition of NPS Pharma today through a merger of one of Shire's subsidiaries with and into NPS Pharma. In connection with the merger, all common shares of NPS Pharma that were not accepted for payment in the tender offer (excluding any shares held by NPS Pharma as treasury stock (other than any shares held in an NPS Pharma benefit plan) and any shares with respect to which the holders have properly demanded appraisal rights in accordance with Delaware law) were converted into the right to receive $46.00 per share in cash, without interest and less any applicable withholding taxes, the same price that will be paid for shares accepted for payment in the tender offer. Following completion of the merger, NPS Pharma became a wholly owned subsidiary of Shire and NPS Pharma's shares ceased to be traded on NASDAQ.
15:59 EDTSHPGValeant to buy Salix for $10.1B, FT says
Subscribe for More Information
February 20, 2015
10:01 EDTDTVOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:40 EDTDTVDirecTV downgraded to Neutral from Buy at Buckingham
Buckingham downgraded DirecTV (DTV) to Neutral based on lack of sufficient upside from the AT&T (T) transaction and views risk/reward as balanced at current levels. Price target lowered to $92 from $95.
07:08 EDTSHPGAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
February 19, 2015
14:42 EDTDTVDirecTV sees FY15 EPS about $6.00, consensus $6.19
Subscribe for More Information
14:14 EDTDTVDirecTV sees weaker subscriber growth in Latin America in 2015 vs. 2014
Subscribe for More Information
14:10 EDTDTVDirecTV looks to keep Brazil margins in 30% range
14:06 EDTDTVDirecTV says on track to close deal with AT&T before end of 1H
Subscribe for More Information
07:33 EDTDTVDirecTV reports Q4 U.S. ARPU up 5% to $117.30
Subscribe for More Information
07:32 EDTDTVDirecTV reports Q4 EPS $1.53, consensus $1.40
Reports Q4 revenue $8.92B, consensus $8.91B. “Our fourth quarter results, although marked by challenging macroeconomic conditions in Latin America and a conscious decision to reinvest in our U.S. business, capped off another strong year of operations for DIRECTV. In Latin America, despite the macroeconomic headwinds, our DIRECTV and Sky brands attracted over 1.4M net new customers - surpassing the 19M cumulative subscriber mark by year-end. More importantly, even excluding Venezuela, DTVLA improved cash flow by over $400M and generated positive cash flow for the year - easily surpassing our internal plans for the business,” said CEO Mike White.
February 18, 2015
15:35 EDTDTVNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Wal-Mart (WMT), consensus $1.54... Priceline (PCLN), consensus $10.10... DIRECTV (DTV), consensus $1.40... Noble Energy (NBL), consensus 35c... Host Hotels & Resorts (HST), consensus 39c... Hormel Foods (HRL), consensus 64c... Discovery Communications (DISCA), consensus 41c... SCANA (SCG), consensus 73c... Quanta Services (PWR), consensus 51c... Patterson (PDCO), consensus 59c... Denbury Resources (DNR), consensus 23c... T-Mobile (TMUS), consensus 5c... Linn Energy (LINE), consensus 6c... Linn Co (LNCO), consensus 39c... Bloomin' Brands (BLMN), consensus 27c... Huntington Ingalls (HII), consensus $1.98.
February 17, 2015
18:06 EDTSHPG, DTV, FDOPaulson & Co gives quarterly update on stakes
Subscribe for More Information
09:29 EDTCOVMedtronic says FY16 constant currency revenue may be up mid-single digit range
Subscribe for More Information
09:27 EDTCOVMedtronic, Covidien targeting over $850M in cost synergies through FY18
Subscribe for More Information
09:12 EDTSHPGShire multiple poised to expand, says SunTrust
SunTrust believes that Shire's rare disease unit will account for 40% of its 2020 sales, versus the company's estimate of about 35%. As a result, the firm expects the company's multiple to "re-rate." The firm thinks that the company's long-term growth outlook is underappreciated, and it keeps a $262 price target and Buy rating on the shares.
08:49 EDTCOVMedtronic sees being at high end of Q4 revenue growth range
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use